Semaglutide 2.4 Mg for the Management of Overweight and Obesity: Systematic Literature Review and Meta-Analysis

References

• World Health Organisation. Obesity and overweight; 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed December 5, 2022.
   Google Scholar
• Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9(1):88. doi:10.1186/1471-2458-9-88
   PubMed Web of Science ®Google Scholar
• Chen X, Pensuksan WC, Lohsoonthorn V, Lertmaharit S, Gelaye B, Williams MA. Obstructive sleep apnea and multiple anthropometric indices of general obesity and abdominal obesity among young adults. Int J Soc Sci Stud. 2014;2(3):89–99. doi:10.11114/ijsss.v2i3.439
   Google Scholar
• Pantalone KM, Hobbs TM, Chagin KM, et al. Prevalence and recognition of obesity and its associated comorbidities: cross-sectional analysis of electronic health record data from a large US integrated health system. BMJ Open. 2017;7(11):e017583. doi:10.1136/bmjopen-2017-017583
   PubMed Web of Science ®Google Scholar
• Wilfley DE, Hayes JF, Balantekin KN, Van Buren DJ, Epstein LH. Behavioral interventions for obesity in children and adults: evidence base, novel approaches, and translation into practice. Am Psychol. 2018;73(8):981–993. doi:10.1037/amp0000293
   PubMed Web of Science ®Google Scholar
• Wing RR, Bray GA, Cassidy-Begay M, et al. Effects of intensive lifestyle intervention on all-cause mortality in older adults with type 2 diabetes and overweight/obesity: results from the look AHEAD study. Diabetes Care. 2022;45(5):1252–1259. doi:10.2337/dc21-1805
   Web of Science ®Google Scholar
• Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145–154.
   PubMed Web of Science ®Google Scholar
• Ryan DH. Drugs for treating obesity. In: Handbook of Experimental Pharmacology. Springer; 2021.
   Google Scholar
• CHMP. QSIVA (phentermine/topiramate). 2013; Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/qsiva. Accessed March 8, 2022.
   Google Scholar
• Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–515. doi:10.1056/NEJMoa2107519
   PubMed Web of Science ®Google Scholar
• Pereira MJ, Eriksson JW. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs. 2019;79(3):219–230. doi:10.1007/s40265-019-1057-0
   PubMed Web of Science ®Google Scholar
• Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183
   PubMed Web of Science ®Google Scholar
• Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metabol. 2019;30:72–130. doi:10.1016/j.molmet.2019.09.010
   PubMed Web of Science ®Google Scholar
• Hinnen D. Glucagon-like peptide 1 receptor agonists for type 2 diabetes. Diabetes Spectr. 2017;30(3):202–210. doi:10.2337/ds16-0026
   PubMedGoogle Scholar
• Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971–984. doi:10.1016/S0140-6736(21)00213-0
   PubMed Web of Science ®Google Scholar
• Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138–150. doi:10.1001/jama.2021.23619
   PubMed Web of Science ®Google Scholar
• PRISMA. PRISMA checklist; 2020. Available from: http://www.prisma-statement.org/PRISMAStatement/Checklist. Accessed March 21, 2022.
   Google Scholar
• CRD. CRD’s guidance for undertaking reviews in health care. Centre for Reviews and Dissemination. University of York; 2009. Available from: https://wwwyorkacuk/media/crd/Systematic_Reviewspdf. Accessed December 5, 2022.
   Google Scholar
• NICE. Single technology appraisal: user guide for company evidence submission template (PMG24); 2015. Available from: https://wwwniceorguk/process/pmg24/resources/single-technology-appraisal-user-guide-for-company-evidence-submission-template-pdf-72286715419333. Accessed December 5, 2022.
   Google Scholar
• Dias S, Welton NJ, Sutton AJ, Ades AE NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials; 2011. Available from: www.nicedsu.org.uk. Accessed December 5, 2022.
   Google Scholar
• Dias S, Welton NJ, Sutton AJ, Valdwell DM, Guobing L, Ades AE NICE DSU technical support document 4: inconsistency in networks of evidence based on randomised controlled trials; 2011. Available from: www.nicedsu.org.uk. Accessed December 5, 2022.
   Google Scholar
• Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. NICE DSU technical support document 4: inconsistency in networks of evidence based on randomised controlled trials; 2011. Available from: http://www.nicedsu.org.uk. Accessed December 5, 2022.
   Google Scholar
• Berne C. A randomized study of orlistat in combination with a weight management programme in obese patients with type 2 diabetes treated with metformin. Diabetic Med. 2005;22(5):612–618. doi:10.1111/j.1464-5491.2004.01474.x
   PubMed Web of Science ®Google Scholar
• Hollander P, Gupta AK, Plodkowski R, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022–4029. doi:10.2337/dc13-0234
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Salvadeo SA, et al. Comparison of orlistat treatment and placebo in obese type 2 diabetic patients. Expert Opin Pharmacother. 2010;11(12):1971–1982. doi:10.1517/14656566.2010.493557
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab. 2002;4(6):415–423. doi:10.1046/j.1463-1326.2002.00237.x
   PubMed Web of Science ®Google Scholar
• Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care. 1998;21(8):1288–1294. doi:10.2337/diacare.21.8.1288
   PubMed Web of Science ®Google Scholar
• Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care. 2002;25(7):1123–1128. doi:10.2337/diacare.25.7.1123
   PubMed Web of Science ®Google Scholar
• Garvey WT, Ryan DH, Bohannon NJ, et al. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care. 2014;37(12):3309–3316. doi:10.2337/dc14-0930
   PubMed Web of Science ®Google Scholar
• Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314(7):687–699. doi:10.1001/jama.2015.9676
   PubMed Web of Science ®Google Scholar
• Garvey WT, Birkenfeld AL, Dicker D, et al. Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the SCALE insulin randomized controlled trial. Diabetes Care. 2020;43(5):1085–1093. doi:10.2337/dc19-1745
   PubMed Web of Science ®Google Scholar
• Lindgärde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med. 2000;248(3):245–254. doi:10.1046/j.1365-2796.2000.00720.x
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski KE, Prcela L, et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA. 2016;315(10):990–1004. doi:10.1001/jama.2016.1558
   PubMed Web of Science ®Google Scholar
• Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341–1352. doi:10.1016/S0140-6736(11)60205-5
   PubMed Web of Science ®Google Scholar
• Williamson DA. Fifty years of behavioral/lifestyle interventions for overweight and obesity: where have we been and where are we going? Obesity. 2017;25(11):1867–1875. doi:10.1002/oby.21914
   PubMed Web of Science ®Google Scholar
• Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403–1413. doi:10.1001/jama.2021.1831
   PubMed Web of Science ®Google Scholar
• Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity. 2011;19(1):110–120. doi:10.1038/oby.2010.147
   PubMed Web of Science ®Google Scholar
• Wadden TA, Walsh OA, Berkowitz RI, et al. Intensive behavioral therapy for obesity combined with liraglutide 3.0 mg: a randomized controlled trial. Obesity. 2019;27(1):75–86. doi:10.1002/oby.22359
   PubMed Web of Science ®Google Scholar
• Wadden TA, Tronieri JS, Sugimoto D, et al. Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial. Obesity. 2020;28(3):529–536. doi:10.1002/oby.22726
   PubMed Web of Science ®Google Scholar
• Poston WS, Reeves RS, Haddock CK, et al. Weight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification. Int J Obes. 2003;27(12):1486–1493. doi:10.1038/sj.ijo.0802439
   PubMed Web of Science ®Google Scholar
• Poston WSC, Haddock CK, Pinkston MM, et al. Evaluation of a primary care-oriented brief counselling intervention for obesity with and without orlistat. J Intern Med. 2006;260(4):388–398. doi:10.1111/j.1365-2796.2006.01702.x
   Web of Science ®Google Scholar
• Lucas CP, Boldrin MN, Reaven GM. Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia. Am J Cardiol. 2003;91(8):961–964. doi:10.1016/S0002-9149(03)00112-7
   PubMed Web of Science ®Google Scholar
• Mathus-Vliegen EMH, van Ierland-van Leeuwen ML, Bennink RJ. Influences of fat restriction and lipase inhibition on gastric emptying in obesity. Int J Obes. 2006;30(8):1203–1210. doi:10.1038/sj.ijo.0803255
   Web of Science ®Google Scholar
• Karhunen L, Franssila-Kallunki A, Rissanen P, et al. Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns. Int J Obes Related Metabol Disord. 2000;24(12):1567–1572. doi:10.1038/sj.ijo.0801443
   Web of Science ®Google Scholar
• Dai H, Alsalhe TA, Chalghaf N, Riccò M, Bragazzi NL, Wu J. The global burden of disease attributable to high body mass index in 195 countries and territories, 1990-2017: an analysis of the Global Burden of Disease Study. PLoS Med. 2020;17(7):e1003198–e1003198. doi:10.1371/journal.pmed.1003198
   PubMed Web of Science ®Google Scholar
• Janssen F, Bardoutsos A, Vidra N. Obesity prevalence in the long-term future in 18 European countries and in the USA. Obes Facts. 2020;13(5):514–527. doi:10.1159/000511023
   PubMed Web of Science ®Google Scholar
• Saxon DR, Iwamoto SJ, Mettenbrink CJ, et al. Antiobesity medication use in 2.2 million adults across eight large health care organizations: 2009–2015. Obesity. 2019;27(12):1975–1981. doi:10.1002/oby.22581
   PubMed Web of Science ®Google Scholar
• Wharton S, Astrup A, Endahl L, et al. Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data. Int J Obes. 2021;45(5):923–933. doi:10.1038/s41366-020-00733-x
   PubMed Web of Science ®Google Scholar
• Schroll JB, Penninga EI, Gøtzsche PC. Assessment of adverse events in protocols, clinical study reports, and published papers of trials of orlistat: a document analysis. PLoS Med. 2016;13(8):e1002101. doi:10.1371/journal.pmed.1002101
   PubMed Web of Science ®Google Scholar
• Cacciottolo TM, Evans K. Research in brief: effective pharmacotherapy for the management of obesity. Clin Med (Northfield Il). 2021;21(5):e517. doi:10.7861/clinmed.2021-0253
   Web of Science ®Google Scholar
• Gao X, Hua X, Wang X, et al. Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2022;13. doi:10.3389/fphar.2022.935823
   Web of Science ®Google Scholar
• Fornes A, Huff J, Pritchard RI, Godfrey M. Once-weekly semaglutide for weight management: a clinical review. J Pharm Technol. 2022;38(4):239–246. doi:10.1177/87551225221092681
   Web of Science ®Google Scholar
• Li J, He K, Ge J, Li C, Jing Z. Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2021;172:108656. doi:10.1016/j.diabres.2021.108656
   Web of Science ®Google Scholar
• Shi Q, Wang Y, Hao Q, et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet. 2022;399(10321):259–269. doi:10.1016/S0140-6736(21)01640-8
   PubMed Web of Science ®Google Scholar
• Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374(9701):1606–1616. doi:10.1016/S0140-6736(09)61375-1
   PubMed Web of Science ®Google Scholar
• O’Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, Phase 2 trial. Lancet. 2018;392(10148):637–649. doi:10.1016/S0140-6736(18)31773-2
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22. doi:10.1056/NEJMoa1411892
   PubMed Web of Science ®Google Scholar
• Bakris G, Calhoun D, Egan B, Hellmann C, Dolker M, Kingma I. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens. 2002;20(11):2257–2267. doi:10.1097/00004872-200211000-00026
   PubMed Web of Science ®Google Scholar
• Broom I, Wilding J, Stott P, Myers N. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. Int J Clin Pract. 2002;56(7):494–499.
   PubMed Web of Science ®Google Scholar
• Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistata randomized controlled trial. JAMA. 1999;281(3):235–242. doi:10.1001/jama.281.3.235
   PubMed Web of Science ®Google Scholar
• Derosa G, Mugellini A, Ciccarelli L, Fogari R. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. Clin Ther. 2003;25(4):1107–1122. doi:10.1016/S0149-2918(03)80070-X
   Web of Science ®Google Scholar
• Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Related Metabol Disord. 2000;24(3):306–313. doi:10.1038/sj.ijo.0801128
   PubMed Web of Science ®Google Scholar
• Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000;9(2):160–167. doi:10.1001/archfami.9.2.160
   PubMedGoogle Scholar
• Krempf M, Louvet JP, Allanic H, Miloradovich T, Joubert JM, Attali JR. Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity. Int J Obes. 2003;27(5):591–597. doi:10.1038/sj.ijo.0802281
   Web of Science ®Google Scholar
• Rössner S, Sjöström L, Noack R, Meinders AE, Noseda G; on behalf of the European Orlistat Obesity Society. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res. 2000;8(1):49–61. doi:10.1038/oby.2000.8
   PubMedGoogle Scholar
• Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998;352(9123):167–172. doi:10.1016/S0140-6736(97)11509-4
   PubMed Web of Science ®Google Scholar
• Swinburn BA, Carey D, Hills AP, et al. Effect of orlistat on cardiovascular disease risk in obese adults. Diabetes Obes Metab. 2005;7(3):254–262. doi:10.1111/j.1463-1326.2004.00467.x
   PubMed Web of Science ®Google Scholar
• Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155–161. doi:10.2337/diacare.27.1.155
   PubMed Web of Science ®Google Scholar
• Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595–605. doi:10.1016/S0140-6736(10)60888-4
   PubMed Web of Science ®Google Scholar
• Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity. 2013;21(5):935–943. doi:10.1002/oby.20309
   PubMed Web of Science ®Google Scholar
• Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity. 2012;20(2):330–342. doi:10.1038/oby.2011.330
   PubMed Web of Science ®Google Scholar